edaravone has been researched along with Anterior Choroidal Artery Infarction in 57 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI)." | 9.51 | The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. ( Shen, QQ; Tong, XW; Wang, W; Wu, H, 2022) |
| " Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined." | 9.41 | Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. ( Li, LD; Shi, SF; Zhou, Y, 2023) |
| "The present study aimed to explore the effects of edaravone on neurological function, tumor necrosis factor α (TNF-α), and interleukin (IL)-8 levels in patients with cerebral infarction." | 9.34 | Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction. ( Li, X; Ma, D; Sun, G, 2020) |
| "Our study aimed to investigate the effect of intravenous thrombolysis with alteplase and edaravone on cerebral hemodynamics and T lymphocyte level in patients harboring acute cerebral infarction." | 9.34 | Effects of intravenous thrombolysis with alteplase combined with edaravone on cerebral hemodynamics and T lymphocyte level in patients with acute cerebral infarction. ( Guo, SF; Li, XX; Liu, SH; Pang, SL; Zhuang, SJ, 2020) |
| "Edaravone can significantly improve the degree of neurological impairment during acute cerebral infarction, functional movement, and living quality with a definite effect and high safety." | 9.30 | Clinical observation in edaravone treatment for acute cerebral infarction. ( Gao, G; Sun, C; Sun, Z; Xu, Q; Zhao, M, 2019) |
| "The objective of this study was to investigate the effects of edaravone combined with oxiracetam on neuronal apoptosis in rats with cerebral infarction (CI) and to explore the potential molecular mechanism." | 8.12 | Effects of edaravone combined with Oxiracetam on neuronal apoptosis in rats with cerebral infarction through targeting SIRT1/NF-κB inflammatory pathway. ( Cui, XP; Lin, H; Mu, JS; Ye, JX; Ye, S; Zhou, H, 2022) |
| "The neuroprotection of acute cerebral infarction (ACI) model by edaravone dexborneol (ED)-mediated Keap1-Nrf2/ARE signal pathway was investigated." | 8.12 | Keap1-Nrf2/ARE Pathway-based Investigation into the Mechanism of Edaravone Dexborneol in Cerebral Infarction Model Neuroprotection. ( Wang, B; Wang, Y; Yang, X, 2022) |
| "To investigate the clinical efficacy and safety of Shenxiong glucose injection combined with edaravone in the treatment of acute large-area cerebral infarction." | 8.02 | A Single-Center Clinical Study to Evaluate Shenxiong Glucose Injection Combined with Edaravone in the Treatment of Acute Large-Area Cerebral Infarction. ( Huang, P; Li, Z; Luo, J; Rong, X; Xu, X; Zeng, T, 2021) |
| "To investigate the effects of penehyclidine combined with edaravone on acute cerebral infarction (ACI) in rats." | 7.88 | Curative efficacy of penehyclidine combined with edaravone on acute cerebral infarction and their effects on serum TNF-α and NDS score in rats. ( Chen, Y; Zhao, Y, 2018) |
| "To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms." | 7.81 | [Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015) |
| "Edaravone attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia." | 7.80 | Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. ( Johshita, H; Miyazaki, H; Okamura, K; Shiokawa, Y; Tsubokawa, T, 2014) |
| "Edaravone is a free radical scavenger that protects the adjacent cortex during cerebral infarction." | 7.79 | Effects of edaravone, a free radical scavenger, on photochemically induced cerebral infarction in a rat hemiplegic model. ( Harada, K; Ikeda, S; Kamikawa, Y; Ohwatashi, A, 2013) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction." | 7.78 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012) |
| "Edaravone, a potent free radical scavenger, is clinically used for the treatment of cerebral infarction in Japan." | 7.75 | The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. ( Arimura, N; Biswas, KK; Hashiguchi, T; Ito, T; Iwata, M; Kawahara, K; Kikuchi, K; Kuramoto, T; Maruyama, I; Matsuda, F; Miura, N; Morimoto, Y; Nakayama, K; Nawa, Y; Oyama, Y; Shigemori, M; Tajima, Y; Takenouchi, K; Tancharoen, S; Yoshida, Y, 2009) |
| "A 60-year-old male with cerebral infarction was admitted to our hospital and treated with edaravone." | 7.74 | A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. ( Abe, M; Kaizu, K; Matsumoto, K, 2007) |
| "Prophylactic administration of edaravone exerted a significant protective effect against postoperative neurologic dysfunction after antegrade selective cerebral perfusion in a canine model with old cerebral infarction." | 7.74 | Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction. ( Akuzawa, S; Bashar, AH; Fujie, M; Kazui, T; Ohishi, K; Ohkura, K; Suzuki, K; Suzuki, T; Terada, H; Washiyama, N; Yamamoto, S; Yamashita, K, 2007) |
| " With use of this system we studied whether human serum obtained from patients with acute cerebral infarction (n = 16) would have a proliferative effect on vessels and whether an administration of a free radical scavenger, edaravone, with or without amlodipine would elicit antiproliferative effects." | 7.72 | [Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells]. ( Echizen, H; Hiraga, M; Ida, T; Kobayashi, T; Oishi, K; Uchida, MK; Yamaguchi, T, 2004) |
| "We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil." | 7.71 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002) |
| "In patients with DINDs, the incidence of cerebral infarction caused by vasospasm was 66% in the control group and 0% in the edaravone-treated group (P = 0." | 6.74 | Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. ( Asano, K; Munakata, A; Nakano, T; Naraoka, M; Ohkuma, H; Shimamura, N, 2009) |
| "Edaravone was administered to 27 randomly selected patients (GIa, n = 13; GIIa, n = 14) and its efficacy was studied by comparing their plasma OxLDL, S-100B, and MnSOD levels to those in patients without edaravone (GIb, n = 11, GIIb, n = 13)." | 6.71 | Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. ( Harada, M; Itabe, H; Kitazato, KT; Matsuzaki, K; Nagahiro, S; Suzue, A; Uno, M, 2005) |
| "This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI)." | 5.51 | The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction. ( Shen, QQ; Tong, XW; Wang, W; Wu, H, 2022) |
| " Whether it can provide better outcomes when combined with edaravone injection (ERI) for the treatment of acute cerebral infarction is not well determined." | 5.41 | Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. ( Li, LD; Shi, SF; Zhou, Y, 2023) |
| "The present study aimed to explore the effects of edaravone on neurological function, tumor necrosis factor α (TNF-α), and interleukin (IL)-8 levels in patients with cerebral infarction." | 5.34 | Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction. ( Li, X; Ma, D; Sun, G, 2020) |
| "Our study aimed to investigate the effect of intravenous thrombolysis with alteplase and edaravone on cerebral hemodynamics and T lymphocyte level in patients harboring acute cerebral infarction." | 5.34 | Effects of intravenous thrombolysis with alteplase combined with edaravone on cerebral hemodynamics and T lymphocyte level in patients with acute cerebral infarction. ( Guo, SF; Li, XX; Liu, SH; Pang, SL; Zhuang, SJ, 2020) |
| "Edaravone can significantly improve the degree of neurological impairment during acute cerebral infarction, functional movement, and living quality with a definite effect and high safety." | 5.30 | Clinical observation in edaravone treatment for acute cerebral infarction. ( Gao, G; Sun, C; Sun, Z; Xu, Q; Zhao, M, 2019) |
| "A rat intracerebral hemorrhage (ICH) model was established by combining FUS and microbubbles (μBs), and edaravone was used to verify whether the free radical scavenger had a protective effect on the model." | 4.31 | A new method for preparing a rat intracerebral hemorrhage model by combining focused ultrasound and microbubbles. ( He, Y; Hu, F; Li, Q; Li, X; Liao, M; Lu, Q; Mei, C; Nie, Y; Song, K; Wu, Z; Yang, J; Zhang, T; Zhong, Z; Zhu, X, 2023) |
| "The neuroprotection of acute cerebral infarction (ACI) model by edaravone dexborneol (ED)-mediated Keap1-Nrf2/ARE signal pathway was investigated." | 4.12 | Keap1-Nrf2/ARE Pathway-based Investigation into the Mechanism of Edaravone Dexborneol in Cerebral Infarction Model Neuroprotection. ( Wang, B; Wang, Y; Yang, X, 2022) |
| "The objective of this study was to investigate the effects of edaravone combined with oxiracetam on neuronal apoptosis in rats with cerebral infarction (CI) and to explore the potential molecular mechanism." | 4.12 | Effects of edaravone combined with Oxiracetam on neuronal apoptosis in rats with cerebral infarction through targeting SIRT1/NF-κB inflammatory pathway. ( Cui, XP; Lin, H; Mu, JS; Ye, JX; Ye, S; Zhou, H, 2022) |
| "This paper aimed to discuss the denoising ability of magnetic resonance imaging (MRI) images based on fuzzy C-means clustering (FCM) algorithm and the influence of Butylphthalide combined with Edaravone treatment on nerve function and vascular endothelial function in patients with acute cerebral infarction (ACI)." | 4.02 | Fuzzy ( Chang, H; Li, H; Wang, D; Yin, A; Yin, J, 2021) |
| "To investigate the clinical efficacy and safety of Shenxiong glucose injection combined with edaravone in the treatment of acute large-area cerebral infarction." | 4.02 | A Single-Center Clinical Study to Evaluate Shenxiong Glucose Injection Combined with Edaravone in the Treatment of Acute Large-Area Cerebral Infarction. ( Huang, P; Li, Z; Luo, J; Rong, X; Xu, X; Zeng, T, 2021) |
| "To investigate the effects of penehyclidine combined with edaravone on acute cerebral infarction (ACI) in rats." | 3.88 | Curative efficacy of penehyclidine combined with edaravone on acute cerebral infarction and their effects on serum TNF-α and NDS score in rats. ( Chen, Y; Zhao, Y, 2018) |
| "To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms." | 3.81 | [Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015) |
| "Edaravone attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia." | 3.80 | Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia. ( Johshita, H; Miyazaki, H; Okamura, K; Shiokawa, Y; Tsubokawa, T, 2014) |
| "Edaravone is a free radical scavenger that protects the adjacent cortex during cerebral infarction." | 3.79 | Effects of edaravone, a free radical scavenger, on photochemically induced cerebral infarction in a rat hemiplegic model. ( Harada, K; Ikeda, S; Kamikawa, Y; Ohwatashi, A, 2013) |
| "Edaravone is a novel free radical scavenger that is clinically employed in patients with acute cerebral infarction." | 3.78 | Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury. ( Chen, X; Gao, M; Lei, S; Li, L; Li, W; Li, X; Liu, Y; Lu, H; Wang, N; Zhang, P; Zheng, J, 2012) |
| "Medical records were retrospectively surveyed to identify patients who had received edaravone treatment for acute-phase cerebral infarction at Kawakita General Hospital, Tokyo, Japan, followed by recovery rehabilitation at Kawakita Rehabilitation Hospital, Tokyo, Japan, for > or = 30 days." | 3.76 | Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy. ( Katayama, M; Shimizu, H; Unno, Y, 2010) |
| "Edaravone, a potent free radical scavenger, is clinically used for the treatment of cerebral infarction in Japan." | 3.75 | The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. ( Arimura, N; Biswas, KK; Hashiguchi, T; Ito, T; Iwata, M; Kawahara, K; Kikuchi, K; Kuramoto, T; Maruyama, I; Matsuda, F; Miura, N; Morimoto, Y; Nakayama, K; Nawa, Y; Oyama, Y; Shigemori, M; Tajima, Y; Takenouchi, K; Tancharoen, S; Yoshida, Y, 2009) |
| "Prophylactic administration of edaravone exerted a significant protective effect against postoperative neurologic dysfunction after antegrade selective cerebral perfusion in a canine model with old cerebral infarction." | 3.74 | Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction. ( Akuzawa, S; Bashar, AH; Fujie, M; Kazui, T; Ohishi, K; Ohkura, K; Suzuki, K; Suzuki, T; Terada, H; Washiyama, N; Yamamoto, S; Yamashita, K, 2007) |
| "A 60-year-old male with cerebral infarction was admitted to our hospital and treated with edaravone." | 3.74 | A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. ( Abe, M; Kaizu, K; Matsumoto, K, 2007) |
| " With use of this system we studied whether human serum obtained from patients with acute cerebral infarction (n = 16) would have a proliferative effect on vessels and whether an administration of a free radical scavenger, edaravone, with or without amlodipine would elicit antiproliferative effects." | 3.72 | [Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells]. ( Echizen, H; Hiraga, M; Ida, T; Kobayashi, T; Oishi, K; Uchida, MK; Yamaguchi, T, 2004) |
| "We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil." | 3.71 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002) |
| "In patients with DINDs, the incidence of cerebral infarction caused by vasospasm was 66% in the control group and 0% in the edaravone-treated group (P = 0." | 2.74 | Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. ( Asano, K; Munakata, A; Nakano, T; Naraoka, M; Ohkuma, H; Shimamura, N, 2009) |
| "Edaravone was infused at a dose of 30 mg, twice a day, for 14 days." | 2.71 | Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. ( , 2003) |
| "Edaravone was associated with delayed evolution of infarcts and edema in patients with severe carotid-territorial stroke and decreased mortality during the acute stage." | 2.71 | Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. ( Arihiro, S; Fujii, K; Ibayashi, S; Iida, M; Kamouchi, M; Nakane, H; Okada, Y; Toyoda, K, 2004) |
| "Pretreatment with edaravone can prevent development of cognitive impairment after CEA." | 2.71 | Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy. ( Endo, H; Fukuda, T; Inoue, T; Kobayashi, M; Ogasawara, K; Ogawa, A; Terasaki, K; Yamadate, K; Yoshida, K, 2005) |
| "Edaravone was administered to 27 randomly selected patients (GIa, n = 13; GIIa, n = 14) and its efficacy was studied by comparing their plasma OxLDL, S-100B, and MnSOD levels to those in patients without edaravone (GIb, n = 11, GIIb, n = 13)." | 2.71 | Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. ( Harada, M; Itabe, H; Kitazato, KT; Matsuzaki, K; Nagahiro, S; Suzue, A; Uno, M, 2005) |
| "Edaravone combined with anticoagulant therapy is a reliable method to enhance ADL and reduce the inflammatory response of ACI patients." | 1.72 | Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF- ( Ma, C; Ma, L; Sun, C; Sun, Y, 2022) |
| "A part of familial Hirschsprung disease has genetic factors in common with cerebrovascular disease." | 1.51 | A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease. ( Abe, K; Hishikawa, N; Ohta, Y; Sasaki, R; Sato, K; Takemoto, M; Yamashita, T, 2019) |
| "Edaravone was treated twice via tail vein; after MCA occlusion and after reperfusion." | 1.43 | A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model. ( Arai, K; Fujiwara, N; Lee, BJ; Lo, EH; Mandeville, ET; Pham, LD; Som, AT, 2016) |
| "On day after discharge, he developed cerebral infarction and showed persistence of multiple left ventricular thrombi." | 1.40 | Multiple left ventricular thrombi in a patient with dilated cardiomyopathy and cerebral infarction: a case report. ( Mine, T; Miyake, H; Sato, I, 2014) |
| "He had been treated for lung cancer by chemotherapy and irradiation 3 years earlier." | 1.40 | [Case of cardiac tamponade during the treatment of acute cerebral infarction]. ( Nagasawa, H; Ono, H; Tanaka, H; Yamakawa, T, 2014) |
| "Mice subjected to 2-h filamental middle cerebral artery occlusion were treated with NBO (95% O2, during the ischemia) alone, with edaravone (1." | 1.35 | Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice. ( Hara, H; Iwama, T; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2008) |
| "In in vitro models of cerebral ischemia, exposure to hydrogen peroxide or glutamate induced cell death with overactivation of PARP, and treatment with DR2313 reduced excessive formation of poly(ADP-ribose) and cell death." | 1.33 | A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. ( Hasegawa, T; Ishikawa, M; Kakui, N; Nakajima, H; Ohkuma, K, 2005) |
| "Edaravone-treated animals showed significantly improved neurological outcome." | 1.33 | Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. ( Amemiya, S; Inaba, T; Kamiya, T; Katayama, Y; Kato, K; Nito, C; Shimazaki, K; Ueda, M, 2005) |
| "Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion." | 1.33 | Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005) |
| "The volume of cerebral infarction, induced by 2-h occlusion and subsequent 2-h reperfusion of MCA in Fisher-344 rats, was evaluated." | 1.30 | Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. ( Iwai, T; Nakashima, M; Niwa, M; Uematsu, T, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.75) | 18.2507 |
| 2000's | 23 (40.35) | 29.6817 |
| 2010's | 19 (33.33) | 24.3611 |
| 2020's | 14 (24.56) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, K | 1 |
| Tao, X | 1 |
| Su, J | 1 |
| Li, F | 1 |
| Mu, F | 1 |
| Zhao, S | 1 |
| Lu, X | 1 |
| Li, J | 1 |
| Chen, S | 1 |
| Dong, T | 1 |
| Duan, J | 1 |
| Wei, P | 1 |
| Xi, M | 1 |
| Cui, XP | 1 |
| Ye, JX | 1 |
| Lin, H | 1 |
| Zhou, H | 1 |
| Ye, S | 1 |
| Mu, JS | 1 |
| Sun, C | 2 |
| Ma, C | 1 |
| Sun, Y | 1 |
| Ma, L | 1 |
| Zhang, XL | 1 |
| Liu, Y | 2 |
| Cheng, X | 1 |
| Li, TT | 1 |
| Shen, QQ | 1 |
| Wang, W | 1 |
| Wu, H | 1 |
| Tong, XW | 1 |
| He, Y | 2 |
| Yang, J | 1 |
| Hu, F | 1 |
| Liao, M | 1 |
| Nie, Y | 1 |
| Zhu, X | 1 |
| Zhang, T | 1 |
| Song, K | 1 |
| Li, Q | 1 |
| Li, X | 3 |
| Mei, C | 1 |
| Wu, Z | 1 |
| Lu, Q | 1 |
| Zhong, Z | 1 |
| Yasutaka, Y | 1 |
| Fujioka, S | 1 |
| Tsuboi, Y | 1 |
| Oyabu, K | 1 |
| Shibaguchi, H | 1 |
| Kamimura, H | 1 |
| Li, LD | 1 |
| Zhou, Y | 1 |
| Shi, SF | 1 |
| Yang, X | 1 |
| Wang, B | 1 |
| Wang, Y | 1 |
| Sun, Z | 1 |
| Xu, Q | 1 |
| Gao, G | 1 |
| Zhao, M | 1 |
| Ma, D | 1 |
| Sun, G | 1 |
| Li, XX | 1 |
| Liu, SH | 1 |
| Zhuang, SJ | 1 |
| Guo, SF | 1 |
| Pang, SL | 1 |
| Li, Z | 1 |
| Rong, X | 1 |
| Luo, J | 1 |
| Zeng, T | 1 |
| Huang, P | 1 |
| Xu, X | 1 |
| Yin, J | 1 |
| Chang, H | 1 |
| Wang, D | 2 |
| Li, H | 1 |
| Yin, A | 1 |
| Chen, Y | 1 |
| Zhao, Y | 1 |
| Sato, K | 1 |
| Sasaki, R | 1 |
| Ohta, Y | 1 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 1 |
| Abe, K | 6 |
| Peng, X | 1 |
| Yang, A | 1 |
| Dong, L | 1 |
| Lu, H | 2 |
| Ikeda, S | 1 |
| Harada, K | 1 |
| Ohwatashi, A | 1 |
| Kamikawa, Y | 1 |
| Okamura, K | 1 |
| Tsubokawa, T | 1 |
| Johshita, H | 1 |
| Miyazaki, H | 1 |
| Shiokawa, Y | 1 |
| Nagasawa, H | 1 |
| Ono, H | 1 |
| Tanaka, H | 1 |
| Yamakawa, T | 1 |
| Yamamoto, Y | 2 |
| Mine, T | 1 |
| Sato, I | 1 |
| Miyake, H | 1 |
| Nishihira, T | 1 |
| Suzuki, K | 2 |
| Takekawa, H | 1 |
| Nakamura, T | 1 |
| Iwasaki, A | 1 |
| Hirata, K | 1 |
| Zhang, S | 1 |
| Hou, S | 1 |
| Chen, H | 1 |
| Fujiwara, N | 1 |
| Som, AT | 1 |
| Pham, LD | 1 |
| Lee, BJ | 1 |
| Mandeville, ET | 1 |
| Lo, EH | 1 |
| Arai, K | 1 |
| Nonaka, Y | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Osaka, H | 1 |
| Okazaki, S | 1 |
| Higashi, Y | 1 |
| Munakata, A | 1 |
| Ohkuma, H | 1 |
| Nakano, T | 1 |
| Shimamura, N | 1 |
| Asano, K | 1 |
| Naraoka, M | 1 |
| Kikuchi, K | 1 |
| Kawahara, K | 1 |
| Tancharoen, S | 1 |
| Matsuda, F | 1 |
| Morimoto, Y | 1 |
| Ito, T | 1 |
| Biswas, KK | 1 |
| Takenouchi, K | 1 |
| Miura, N | 1 |
| Oyama, Y | 1 |
| Nawa, Y | 1 |
| Arimura, N | 1 |
| Iwata, M | 1 |
| Tajima, Y | 1 |
| Kuramoto, T | 1 |
| Nakayama, K | 1 |
| Shigemori, M | 1 |
| Yoshida, Y | 1 |
| Hashiguchi, T | 1 |
| Maruyama, I | 1 |
| Yamasaki, H | 1 |
| Matsubara, S | 1 |
| Sasaki, I | 1 |
| Nagahiro, S | 2 |
| Unno, Y | 1 |
| Katayama, M | 1 |
| Shimizu, H | 1 |
| Shibata, K | 1 |
| Hashimoto, T | 1 |
| Nobe, K | 1 |
| Hasumi, K | 1 |
| Honda, K | 1 |
| Liu, N | 1 |
| Shang, J | 1 |
| Tian, F | 1 |
| Nishi, H | 1 |
| Kamiya, T | 2 |
| Ohara, T | 1 |
| Nagakane, Y | 1 |
| Tanaka, E | 1 |
| Morii, F | 1 |
| Koizumi, T | 1 |
| Zhang, P | 1 |
| Li, W | 1 |
| Li, L | 1 |
| Wang, N | 1 |
| Gao, M | 1 |
| Zheng, J | 1 |
| Lei, S | 1 |
| Chen, X | 1 |
| Shinohara, Y | 1 |
| Inoue, S | 1 |
| Takabatake, Y | 1 |
| Uno, E | 1 |
| Wakamatsu, K | 1 |
| Yamazaki, N | 1 |
| Hashimoto, N | 1 |
| Tsuchiya, Y | 1 |
| Yamaguchi, T | 1 |
| Ida, T | 1 |
| Kobayashi, T | 1 |
| Hiraga, M | 1 |
| Oishi, K | 1 |
| Uchida, MK | 1 |
| Echizen, H | 1 |
| Toyoda, K | 1 |
| Fujii, K | 1 |
| Kamouchi, M | 1 |
| Nakane, H | 1 |
| Arihiro, S | 1 |
| Okada, Y | 1 |
| Ibayashi, S | 1 |
| Iida, M | 1 |
| Nakajima, H | 1 |
| Kakui, N | 1 |
| Ohkuma, K | 1 |
| Ishikawa, M | 1 |
| Hasegawa, T | 1 |
| Fushimi, H | 1 |
| Amemiya, S | 1 |
| Nito, C | 1 |
| Inaba, T | 1 |
| Kato, K | 1 |
| Ueda, M | 1 |
| Shimazaki, K | 1 |
| Katayama, Y | 1 |
| Lee, JH | 1 |
| Park, SY | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Ogasawara, K | 1 |
| Yamadate, K | 1 |
| Kobayashi, M | 1 |
| Endo, H | 1 |
| Fukuda, T | 1 |
| Yoshida, K | 1 |
| Terasaki, K | 1 |
| Inoue, T | 1 |
| Ogawa, A | 1 |
| Uno, M | 1 |
| Kitazato, KT | 1 |
| Suzue, A | 1 |
| Matsuzaki, K | 1 |
| Harada, M | 1 |
| Itabe, H | 1 |
| Wen, J | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Yamaguchi, K | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Suzuki, T | 1 |
| Kazui, T | 1 |
| Yamamoto, S | 1 |
| Washiyama, N | 1 |
| Ohkura, K | 1 |
| Ohishi, K | 1 |
| Bashar, AH | 1 |
| Yamashita, K | 1 |
| Terada, H | 1 |
| Akuzawa, S | 1 |
| Fujie, M | 1 |
| Abe, M | 1 |
| Kaizu, K | 1 |
| Matsumoto, K | 1 |
| Niyaz, M | 1 |
| Numakawa, T | 1 |
| Matsuki, Y | 1 |
| Kumamaru, E | 1 |
| Adachi, N | 1 |
| Kitazawa, H | 1 |
| Kunugi, H | 1 |
| Kudo, M | 1 |
| Nakashima, M | 1 |
| Niwa, M | 1 |
| Iwai, T | 1 |
| Uematsu, T | 1 |
| Jin, YJ | 1 |
| Mima, T | 1 |
| Raicu, V | 1 |
| Park, KC | 1 |
| Shimizu, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Nerve Growth Factor or Edaravone on Alcohol-induced Brain Injury[NCT03968042] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-06-30 | Recruiting | ||
| Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy[NCT00153946] | Phase 4 | 814 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for edaravone and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis.
Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Edaravone; Humans; Stroke | 2023 |
[Concept, pathophysiology and treatment for branch atheromatous disease].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Clopidogrel; Contraindications; Drug Therapy, | 2014 |
Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress.
Topics: Acute Disease; Antipyrine; Cerebral Infarction; Edaravone; Endothelium, Vascular; Free Radical Scave | 2009 |
[Future neuroprotective strategies in the post-thrombolysis era--neurovascular unit protection and vascular endothelial protection].
Topics: Amines; Animals; Antipyrine; Cerebral Infarction; Cyclohexanecarboxylic Acids; Edaravone; Endotheliu | 2011 |
[Concept of branch atheromatous disease (BAD) and its clinical significance].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans; | 2010 |
[Gene therapy and neuroprotection for cerebral infarction].
Topics: Adenoviridae; Animals; Antipyrine; Cerebral Infarction; Cerebrovascular Circulation; Edaravone; Free | 2003 |
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scaven | 2005 |
[Edaravone].
Topics: Antipyrine; Cerebral Infarction; Edaravone; Free Radical Scavengers; Humans | 2006 |
9 trials available for edaravone and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction.
Topics: Acute Disease; Brain Ischemia; Cerebral Infarction; Edaravone; Humans; Interleukin-10; Phosphopyruva | 2022 |
Clinical observation in edaravone treatment for acute cerebral infarction.
Topics: Activities of Daily Living; Aged; Cerebral Infarction; Edaravone; Female; Free Radical Scavengers; H | 2019 |
Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction.
Topics: Activities of Daily Living; Aged; Cerebral Infarction; Edaravone; Female; Humans; Interleukin-8; Mal | 2020 |
Effects of intravenous thrombolysis with alteplase combined with edaravone on cerebral hemodynamics and T lymphocyte level in patients with acute cerebral infarction.
Topics: Acute Disease; Administration, Intravenous; Adult; Aged; Cerebral Infarction; Cerebrovascular Circul | 2020 |
Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage.
Topics: Antipyrine; Cerebral Infarction; Comorbidity; Edaravone; Female; Free Radical Scavengers; Humans; Ja | 2009 |
Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antipyrine; Cerebral Infarction; Double-Blind Method; | 2003 |
Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion.
Topics: Aged; Antipyrine; Atrial Fibrillation; Brain Edema; Carotid Artery Thrombosis; Carotid Artery, Inter | 2004 |
Effects of the free radical scavenger, edaravone, on the development of postoperative cognitive impairment in patients undergoing carotid endarterectomy.
Topics: Aged; Antipyrine; Carotid Artery, Internal; Carotid Stenosis; Cerebral Infarction; Cerebrovascular C | 2005 |
Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Astrocytes; Biomarkers; Cerebral Infarction; Edaravone; | 2005 |
40 other studies available for edaravone and Anterior Choroidal Artery Infarction
| Article | Year |
|---|---|
Network pharmacology and molecular docking reveal the effective substances and active mechanisms of Dalbergia Odoriferain protecting against ischemic stroke.
Topics: Animals; Cell Survival; Cerebral Infarction; Dalbergia; Drugs, Chinese Herbal; Edaravone; Gene Expre | 2021 |
Effects of edaravone combined with Oxiracetam on neuronal apoptosis in rats with cerebral infarction through targeting SIRT1/NF-κB inflammatory pathway.
Topics: Animals; Apoptosis; Cerebral Infarction; Edaravone; NF-kappa B; Pyrrolidines; Rats; Rats, Sprague-Da | 2022 |
Effect of Edaravone Combined with Anticoagulant Therapy on the Serum hs-CRP, IL-6, and TNF-
Topics: Anticoagulants; C-Reactive Protein; Cerebral Infarction; Edaravone; Humans; Interleukin-6; Retrospec | 2022 |
Effect of edaravone dexborneol on the serum levels of lipoprotein-related phospholipase A2 and high-sensitivity C-reactive protein in patients with acute cerebral infarction.
Topics: C-Reactive Protein; Cerebral Infarction; Edaravone; Humans; Lipoproteins; Phospholipases A2 | 2023 |
A new method for preparing a rat intracerebral hemorrhage model by combining focused ultrasound and microbubbles.
Topics: Animals; Cerebral Hemorrhage; Cerebral Infarction; Edaravone; Microbubbles; Necrosis; Rats; Rats, Sp | 2023 |
Liver toxicity of intravenous heparin treatment in patients with acute ischemic stroke.
Topics: Anticoagulants; Cerebral Infarction; Edaravone; Enoxaparin; Heparin; Humans; Ischemic Stroke; Liver; | 2023 |
Keap1-Nrf2/ARE Pathway-based Investigation into the Mechanism of Edaravone Dexborneol in Cerebral Infarction Model Neuroprotection.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Edaravone; Inflammation; Kelch-Like ECH-Associated Pro | 2022 |
A Single-Center Clinical Study to Evaluate Shenxiong Glucose Injection Combined with Edaravone in the Treatment of Acute Large-Area Cerebral Infarction.
Topics: Acute Disease; C-Reactive Protein; Cerebral Infarction; Drug Therapy, Combination; Drugs, Chinese He | 2021 |
Fuzzy
Topics: Algorithms; Benzofurans; Biomarkers; Cerebral Infarction; Drug Therapy, Combination; Edaravone; Endo | 2021 |
Curative efficacy of penehyclidine combined with edaravone on acute cerebral infarction and their effects on serum TNF-α and NDS score in rats.
Topics: Acute Disease; Animals; Cerebral Infarction; Edaravone; HMGB1 Protein; Interleukin-6; Quinuclidines; | 2018 |
A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease.
Topics: Adult; Aspirin; Cerebral Angiography; Cerebral Infarction; Cilostazol; Diffusion Magnetic Resonance | 2019 |
Edaravone promotes nerve function recovery after acute cerebral infarction in rats via targeting Keap1-Nrf2/ARE.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Edaravone; Free Radical Scavengers; Kelch-Like ECH-Ass | 2021 |
Effects of edaravone, a free radical scavenger, on photochemically induced cerebral infarction in a rat hemiplegic model.
Topics: Animals; Antipyrine; Cerebral Infarction; Edaravone; Free Radical Scavengers; Hemiplegia; Intracrani | 2013 |
Edaravone, a free radical scavenger, attenuates cerebral infarction and hemorrhagic infarction in rats with hyperglycemia.
Topics: Animals; Antipyrine; Blood Glucose; Brain; Cerebral Hemorrhage; Cerebral Infarction; Edaravone; Free | 2014 |
[Case of cardiac tamponade during the treatment of acute cerebral infarction].
Topics: Acute Disease; Adenocarcinoma; Anterior Cerebral Artery; Antipyrine; Aspirin; Cardiac Tamponade; Cer | 2014 |
Multiple left ventricular thrombi in a patient with dilated cardiomyopathy and cerebral infarction: a case report.
Topics: Aged; Anticoagulants; Antipyrine; Cardiomyopathy, Dilated; Cerebral Infarction; Edaravone; Heart Dis | 2014 |
[Lateral medullary infarction presenting with truncal lateropulsion and decreased pain and temperature sensation below T10 sensory level].
Topics: Antipyrine; Arginine; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Edaravone; Free R | 2014 |
[Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury
in rats and its underlying mechanism].
Topics: Animals; Antipyrine; Brain Edema; Brain Ischemia; Cerebral Infarction; Edaravone; Lactates; Malondia | 2015 |
A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model.
Topics: Animals; Antipyrine; Brain Edema; Cerebral Infarction; Cytokines; Edaravone; Free Radical Scavengers | 2016 |
Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice.
Topics: Animals; Antipyrine; Blood Pressure; Cell Death; Cerebral Infarction; Disease Models, Animal; Edarav | 2008 |
[Outcome assessment in treatment of edaravone in childhood ischemic stroke].
Topics: Adolescent; Antipyrine; Cerebral Infarction; Child; Child, Preschool; Edaravone; Female; Free Radica | 2008 |
The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells.
Topics: Active Transport, Cell Nucleus; Animals; Antipyrine; Apoptosis; Butadienes; Cell Hypoxia; Cell Nucle | 2009 |
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S | 2009 |
Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment? A retrospective study of edaravone therapy.
Topics: Aged; Aged, 80 and over; Antipyrine; Cerebral Infarction; Dose-Response Relationship, Drug; Edaravon | 2010 |
Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice.
Topics: Aldehydes; Animals; Antipyrine; Benzopyrans; Brain; Cerebral Infarction; Disease Models, Animal; Eda | 2011 |
In vivo optical imaging for evaluating the efficacy of edaravone after transient cerebral ischemia in mice.
Topics: Animals; Annexin A5; Antipyrine; Apoptosis; Autophagy; Blood-Brain Barrier; Blotting, Western; Cereb | 2011 |
Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury.
Topics: Analysis of Variance; Animals; Antipyrine; Bromodeoxyuridine; Cerebral Infarction; Cerebral Ventricl | 2012 |
[Therapeutic time window for ischemic stroke].
Topics: Antipyrine; Cerebral Infarction; Edaravone; Fibrinolytic Agents; Free Radical Scavengers; Humans; Ti | 2011 |
Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction.
Topics: Aged; Antipyrine; Cerebral Infarction; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Dru | 2013 |
[The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction].
Topics: Aged; Antipyrine; Cerebral Infarction; Drug Therapy, Combination; Edaravone; Female; Fibrinolytic Ag | 2003 |
[Alterations of antiproliferative effects of serum obtained from patients with acute cerebral infarction treated with a radical scavenger, edaravone, with or without amlodipine using an in vitro cultured basilar artery smooth muscle cells].
Topics: Acute Disease; Aged; Amlodipine; Animals; Antioxidants; Antipyrine; Basilar Artery; Calcium Channel | 2004 |
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured | 2005 |
Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats.
Topics: Animals; Antipyrine; Apoptosis; bcl-2-Associated X Protein; Brain Edema; Brain Ischemia; Cerebral Co | 2005 |
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede | 2005 |
Edaravone inhibits JNK-c-Jun pathway and restores anti-oxidative defense after ischemia-reperfusion injury in aged rats.
Topics: Aging; Animals; Antioxidants; Antipyrine; Blotting, Western; Brain; Cerebral Infarction; Edaravone; | 2006 |
Effect of prophylactically administered edaravone during antegrade cerebral perfusion in a canine model of old cerebral infarction.
Topics: Analysis of Variance; Animals; Antipyrine; Blood Chemical Analysis; Cardiopulmonary Bypass; Cerebral | 2007 |
A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient.
Topics: Acute Kidney Injury; Antipyrine; Cerebral Infarction; Disseminated Intravascular Coagulation; Edarav | 2007 |
MCI-186 prevents brain tissue from neuronal damage in cerebral infarction through the activation of intracellular signaling.
Topics: Animals; Animals, Newborn; Antipyrine; Brain Edema; Butadienes; Cell Death; Cells, Cultured; Cerebra | 2007 |
Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat.
Topics: Animals; Antipyrine; Brain; Caudate Nucleus; Cerebral Infarction; Cyclic N-Oxides; Disease Models, A | 1999 |
Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils.
Topics: Animals; Anticoagulants; Antipyrine; Arginine; Body Water; Brain Edema; Brain Ischemia; Cerebral Inf | 2002 |